1. Market Research
  2. > Biotechnology Market Trends
  3. > Human Papilloma Virus Partnering 2010-2015

Human Papilloma Virus Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

Summary
The Human Papilloma Virus Partnering 2010-2015 report provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Human Papilloma virus Partnering 2010-2015 report provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in human papilloma virus partnering deals
Top human papilloma virus deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Human Papilloma virus Partnering 2010-2015 provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of human papilloma virus partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors human papilloma virus technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 45 links to online copies of actual human papilloma virus deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of human papilloma virus partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of human papilloma virus technologies and products.

Report scope

Human papilloma virus Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to human papilloma virus trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in human papilloma virus dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 45 human papilloma virus deals
The leading human papilloma virus deals by value since 2010

In Human papilloma virus Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Human Papilloma Virus Partnering 2010-2015 provides the reader with the following key benefits:


•In-depth understanding of human papilloma virus deal trends since 2010
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 45 actual human papilloma virus deals entered into by the world’s biopharma companies since 2010
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Keywords

human papilloma virus, hpv, infective, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Human Papilloma Virus Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in human papilloma virus partnering

2.1. Introduction
2.2. Human papilloma virus partnering over the years
2.3. Human papilloma virus partnering by deal type
2.4. Human papilloma virus partnering industry sector
2.5. Human papilloma virus partnering by stage of development
2.6. Human papilloma virus partnering by technology type

Chapter 3 - Average deal terms for human papilloma virus

3.1 Introduction
3.2 Average deal terms for human papilloma virus
3.3 Human papilloma virus headline values with median calculation
3.4 Human papilloma virus upfront values with median calculation
3.5 Human papilloma virus milestone values with median calculation
3.6 Human papilloma virus royalty rates with median calculation

Chapter 4 - Active human papilloma virus dealmakers

4.1. Introduction
4.2 Most active human papilloma virus dealmakers
4.3. Top human papilloma virus deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Human papilloma virus dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Human papilloma virus partnering since 2010
Figure 2: Human papilloma virus dealmaking activity- 2010 to 2015
Figure 3: Human papilloma virus partnering by deal type since 2010
Figure 4: Human papilloma virus partnering by industry sector since 2010
Figure 5: Human papilloma virus partnering by stage of development since 2010
Figure 6: Human papilloma virus partnering by technology type since 2010
Figure 7: Human papilloma virus deals with a headline value
Figure 8: Human papilloma virus deals with upfront payment values
Figure 9: Human papilloma virus deals with milestone payments
Figure 10: Human papilloma virus deals with royalty rates, %
Figure 11: Top human papilloma virus deals by value since 2010
Figure 12: Big pharma - top 50 - human papilloma virus deals 2010 to 2015
Figure 13: Big pharma human papilloma virus deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - human papilloma virus deals 2010 to 2015
Figure 15: Big biotech human papilloma virus deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016-2020 Future Horizons and Growth Strategies in the World Cancer Diagnostics Market: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

2016-2020 Future Horizons and Growth Strategies in the World Cancer Diagnostics Market: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21 100
  • Industry report
  • March 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities ...

Global Cancer Diagnostics Market New Frontiers, Business Challenges, Emerging Technologies, Competitive Landscape

Global Cancer Diagnostics Market New Frontiers, Business Challenges, Emerging Technologies, Competitive Landscape

  • $ 21 100
  • Industry report
  • July 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a study of the major business opportunities emerging in the global cance ...

2016-2020 Europe Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities--France, Germany, Italy, Spain, UK

2016-2020 Europe Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities--France, Germany, Italy, Spain, UK

  • $ 12 800
  • Industry report
  • May 2016
  • by Venture Planning Group

Complete report $19,700.DataPack (test volumes, sales forecasts, supplier shares) $12,800.Summary This comprehensive five-country report contains 820 pages, 320 tables, and presents analysis of the majo ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.